Factors Associated with the Risk of Liver Enzyme Elevation in Patients with Type 2 Diabetes Treated with a Thiazolidinedione (original) (raw)

Pharmacotherapy, 2001

Abstract

To characterize frequency of liver enzyme elevation in patients with type 2 diabetes mellitus receiving troglitazone. Retrospective study. Hospital-affiliated medical center. Two hundred ninety-one patients with type 2 diabetes mellitus. Data from patients with an average troglitazone exposure of 412.7 +/- 255.6 days were studied. Enzyme elevations more than 1.5 times the upper limit of normal (ULN) occurred in 17 patients (5.8%) and more than 3-fold elevations in 6 (2.1%). The relationship among enzyme elevation events, demographic factors, duration of troglitazone exposure, frequency of monitoring, and concurrent drugs (limited to glucose and lipid-lowering agents) was assessed by multiple logistic regression. Age was an independent predictor of risk (p=0.009), and concurrent insulin therapy approached statistical significance (p=0.051) for 1.5-fold ULN elevation in liver enzymes. Age and concurrent therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors were the only significant predictors of 3-fold ULN elevations (p=0.03 and p=0.04, respectively). Several factors appear to increase the risk of enzyme elevation events in patients treated with troglitazone.

John St Peter hasn't uploaded this paper.

Let John know you want this paper to be uploaded.

Ask for this paper to be uploaded.